German Journal of Pharmaceuticals and Biomaterials

Drug Repurposing in Personalized Medicine: Translational Pathways and Recommendations

Kelechi Wisdom Elechi — 2025-12-16

This review examines the integration of drug repurposing and personalized medicine as complementary approaches to transforming healthcare delivery. Drug repurposing identifies new therapeutic uses for existing medications with established safety profiles, while personalized medicine tailors treatments to individual patient characteristics. This integration offers reduced development time and costs, expanded options for rare and complex diseases, and targeted interventions based on patient-specific biomarkers. The manuscript explores translational pathways, including drug-centric, target-centric, and disease-centric approaches, as well as emerging computational and AI methodologies. Case studies in neurological disorders, oncology, and seizure disorders demonstrate successful applications. Despite promising outcomes, challenges persist across regulatory frameworks, intellectual property protection, data integration, and the management of biological variability among patients. Recommendations include strengthening regulatory support, developing robust validation pipelines, promoting open-source, collaborative models, and leveraging AI and big data technologies. Through coordinated stakeholder efforts, drug repurposing in personalized medicine can become a cornerstone of precision healthcare, providing more effective, patient-tailored treatments.

Studies on the production and optimization of yellow pigment extracted from the SB2 strain and evaluation of its antioxidant properties

Sandanakirouchenane Aroumougame — 2025-12-16

Actinobacteria are filamentous bacteria that exist independently in soil, oceans, and the atmosphere, producing secondary metabolites with antioxidant and anti-cancer properties. Among these, the SB2 strain is a yellow-pigmented, gram-positive, coccus-shaped bacterium. Raman spectroscopy of SB2 cultures revealed a wave number (cm-1) of 1382.47, which indicates pigment production and was further supported by UV-Vis spectral analysis at 450 nm that confirmed the presence of carotenoid pigment in methanolic extracts of SB2. For optimal pigment synthesis, SB2 required a pH of 7, a temperature of 30 °C, and a nutritional medium with 1% molasses, 1.2% olive oil, and 1% peptone. The yellow pigment extracted from SB2 (500 μg ml-1) demonstrated DPPH (2,2-diphenyl-1-picrylhydrazyl) radical scavenging activity.

Exploring the leaf fractions of Landolphia owariensis P. Beauv. for bioactive constituents, in vivo and beta hematin inhibitory antimalarial activity

Chinelo Henrietta Okonkwo — 2025-12-16

Malaria remains a global challenge even though it is preventable and curable. The study assessed the chemosuppressive efficacy and in vitro antiplasmodial activity of the methanol fraction and subfractions of Landolphia owariensis leaves. The subfractions of Landolphia owariensis leaves obtained from column separation of methanol fractions were investigated for chemosuppressive activity in mice and in vitro antiplasmodial activity using a beta-hematin inhibition assay. Cytotoxicity was determined using the Brine shrimp lethality assay (BSLA), while the active constituents were identified using GC-MS and NMR spectroscopy. The subfractions showed significant chemosuppressive effects against P. berghei at 100 mg/kg when compared with the negative control. The CF5 showed the highest parasite clearance and a chemosuppression of 88.14%. The beta hematin inhibitory activities of C9 (IC50= 93.3 ± 0.05 μg/ml), C9A [octadecanoic acid (IC50 = 91.18 ± 0.07 μg/ml)] were comparable with chloroquine (IC50 = 89.7 ± 0.11 μg/ml). In the BSLA, C9 elicited medium cytotoxic activity (LD50 190.6 ± 0.03 μg/ml). The GC-MS analysis of C9 identified 50 compounds, and the NMR spectrum of C9A indicated the presence of octadecanoic acid. The study suggests that the plant contains constituents that may be explored in the fight against malaria.